Login to Your Account

Regulatory NEWS

The issue of indirect costs associated with federally funded research has a special resonance, given the Trump administration's expressed interest in such matters.

In a move that took no one by surprise, the Trump administration has released a budget proposal for fiscal 2018 that calls for nearly $6 billion in cuts to the NIH budget.

FDA briefing documents framing a Wednesday ODAC review of Puma Biotechnology Inc.'s lead candidate, neratinib, highlight tolerability and trial amendment issues, but still appear supportive of the drug's efficacy as an extended adjuvant treatment for HER2-positive early stage breast cancer.

More Regulatory Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: